~~<i id='B7496B8542'><strike id='B7496B8542'><tt id='B7496B8542'><pre id='B7496B8542'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：knowledge 2025-09-27 22:59:47 - browse：2

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Flu vaccine reformulation won't be easy, manufacturers warn

entertainment

focus

hotspot

knowledge

focus

AdobeWASHINGTON—PharmaceuticalcompaniesaredoinganythingtheycantostopPresidentBiden’sMedicareprogramf

WSS

Congress: Eradicate hepatitis C and reduce the deficit

Immunocompromised patients offer clues on chronic Covid

Printout prescription drug information shouldn’t go digital

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Future doctors need a strong humanities education

Congress likely to miss an opportunity to fix drug shortages issue

leisure time

focus

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Woman gored by Bison at Yellowstone

Jerome Adams on the need for new antivirals for Covid

A pediatrician calls for Congress to pass the child tax credit deal

23andMe had bad news about my health. I wish a person had delivered it

FDA sets aggressive timeline for overhauling inspection procedures

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Woman gored by Bison at Yellowstone

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

To bolster infectious disease surveillance, genomics powerhouses team up

focus

Congress: Eradicate hepatitis C and reduce the deficit

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Grail faces three suits alleging harassment, retaliation

Celiac disease study examines precisely how gluten triggers injury

Who gets to use the title 'doctor'?

Why police arrested suspected Gilgo Beach killer away from his house

hotspot

knowledge

focus

focus